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Abstract Older asthmatic patients may develop fixed
airway obstruction and clinical signs of chronic obstruc-
tive pulmonary disease (COPD). We investigated the
added value of pathological evaluation of bronchial bi-
opsies to help differentiate asthma from COPD, taking
into account smoking, age, and inhaled corticosteroid
(ICS) use. Asthma and COPD patients (24 of each cat-
egory) were matched for ICS use, age, FEV1, and
smoking habits. Five pulmonary and five general pathol-
ogists examined bronchial biopsies using an interactive
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website, without knowing patient information. They
were asked to diagnose asthma or COPD on biopsy
findings in both a pairwise and randomly mixed order
of cases during four different phases, with intervals of
4–6 weeks, covering a maximal period of 36 weeks.
Clinically concordant diagnoses of asthma or COPD
varied between 63 %-73 %, without important differ-
ences between pairwise vs randomly mixed examination
or between general vs pulmonary pathologists. The
highest percentage of concordant diagnoses was in
young asthmatic patients without ICS use and in COPD
patients with ICS use. In non ICS users with fixed
airway obstruction, a COPD diagnosis was favored if
abnormal presence of glands, squamous metaplasia,
and submucosal infiltrate was present and an asthma
diagnosis in case of abnormal presence of goblet cells.
In ICS users with fixed airway obstruction, abnormal
presence of submucosal infiltrates, basement membrane
thickening, eosinophils, and glands was associated with
asthma. Histological characteristics in bronchial biopsies
are reproducibly recognized by pathologists, yet the dif-
ferentiation by histopathology between asthma and
COPD is difficult without information about ICS use.
Keywords Asthma . COPD . AsthmaCOPDOverlap
Syndrome . Pathology
Introduction
Asthma and chronic obstructive pulmonary disease
(COPD) are heterogeneous chronic lung diseases, char-
acterized by the presence of airway obstruction and
airway inflammation [1, 2]. In asthma, airway obstruc-
tion is typically completely or nearly completely re-
versible [2], while irreversible airway obstruction is
typical for COPD [1]. Although both diseases have
overlapping clinical features, acknowledged in guide-
lines [3], they are generally regarded as different dis-
orders; each requiring their own diagnostic and man-
agement strategies. For example, for the pharmacolog-
ical management of asthma, inhaled corticosteroids
(ICSs) are the most efficacious drugs currently avail-
able [2]. In COPD, inhaled bronchodilators are funda-
mental for treatment, whereas addition of ICS is only
recommended for COPD patients suffering from severe
disease (FEV1 < 50 % predicted) and/or a history of
recurrent exacerbations [1]. In order to determine ap-
propriate treatment, prognosis and follow-up, interna-
tional guidelines have emphasized the importance of
differentiating asthma from COPD.
In general, careful history taking, physical examina-
tion, and lung function testing often lead to a clear
diagnosis [4]. However, it is frequently difficult if not
impossible to achieve an accurate diagnosis of either
asthma or COPD in older patients [5–8]. Although asth-
ma generally affects children and young adults, it is not
uncommon that asthma starts later in life [9]. In approx-
imately 4 to 8 % of asthmatic cases, the first asthma
symptoms are present in late adulthood (late-onset
asthma) or even after 65 years of age. With increasing
age, a proportion of patients with asthma may develop
persistent irreversible airflow limitation, particularly in
the presence of risk factors such as smoking [5], blood
eosinophilia, chronic mucus hypersecretion, and a low
level of FEV1 [10]. This type of asthma is clinically
indistinguishable from COPD, which the guidelines
called ACOS or asthma-COPD overlap syndrome [3],
and medical history, physical examination, and lung
function tests may become insufficient to distinguish
asthma from COPD to allow the most adequate therapy.
The lack of a diagnostic standard to identify asthma at
older age, together with poor perception of symptoms
such as dyspnea, may further hamper the recognition
of asthma in the elderly [11].
In case of doubt, clinicians may attempt to achieve a
best possible diagnosis of asthma or COPD by taking
bronchial biopsies for histopathological examination,
although this is not a common practice. It has been
suggested that pathological examination of bronchial
tissue, taking features such as denudation of the epi-
thelium in asthma and epithelial hyperplasia in COPD
into account, might contribute to resolving the diagnos-
tic difficulty. Despite clear morphological differences
between asthma and COPD, some morphological char-
acteristics can be found in both diseases (in particular
584 Virchows Arch (2015) 467:583–593
4 Department of Epidemiology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands
5 Department of Pathology, Spaarne Gasthuis Haarlem-Zuid,
Haarlem, The Netherlands
6 Department of Pathology, Elisabeth-TweeSteden Ziekenhuis,
Tilburg, The Netherlands
7 Department of Pathology, VU Medical Center,
Amsterdam, The Netherlands
8 Department of Pathology, Sao Paulo University, Sao Paulo, Brazil
9 Institute of Pathology, Research Unit Molecular Lung and Pleura
Pathology, Medical University Graz, Graz, Austria
10 Department of Surgical Pathology, University of Zurich,
Zurich, Switzerland
11 Department Pathology, University of British Columbia,
Vancouver, B.C., Canada
12 Department of General Practice, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands
in chronic or severe cases), which impairs their diag-
nostic value in an individual case [12]. Bourdin et al.
demonstrated that the diagnostic value of histological
examination of endobronchial biopsies from subjects
with asthma or COPD is limited, sensitivity and spec-
ificity ranging between 36–48 and 56–79 % respective-
ly [13]. However, the latter study included mostly
young, never-smoking, non-steroid-using asthma pa-
tients with normal lung function and high bronchodila-
tor reversibility. Furthermore, asthma and COPD pa-
tients were not matched for age, airway obstruction,
ICS use, and smoking habits. Since these factors mod-
ulate histological features of airway inflammation and
remodeling, they therefore may have confounded the
results.
In the current study, we aimed to identify the most impor-
tant histopathological features to differentiate between asthma
and COPD in bronchial biopsies. We hypothesized that the
accuracy of the pathological diagnosis would improve when
taking into account modulating factors such as smoking, age,
and ICS use.
Materials and methods
Patients and matching of biopsies
Biopsies from 24 asthma and 24 matched (see below)
COPD patients were included. Subjects were only in-
cluded when there was no uncertainty in the diagnosis
and when subjects met all criteria for either asthma or
COPD according to international guidelines [1, 2]. Sub-
jects were selected from several asthma and COPD co-
hort studies performed in our institute [14–17]. We cre-
ated three groups (A–C) of asthma patients (n = 8 each
group), carefully matched with three groups of COPD
patients (n = 8 each group).
A. The first asthma and COPD groups included subjects
who did not use ICS, were >45 years old, had a post-
bronchodilator (BD) FEV1/FVC <70%, and had smoked
>10 pack-years.
B. The second asthma and COPD groups included subjects
with the same criteria, but subjects had used ICS during
the last 30 months.
C. The third group included asthma patients without ICS
use, and with post-BD FEV1 > 90 % predicted,
age < 45 years, 0 pack-years smoking, and atopy
(Phadiatop > 1.0). This was contrasted with COPD pa-
tients without ICS use, with post-BD FEV1 < 50 % pre-
dicted, age > 45 years, current smoking with >10 pack-
years, and without atopy.
Groups A and B included patients with a clinically difficult
differential diagnosis between asthma and COPD, whereas
control group C included so-called classical cases easy to
differentiate.
Table 1 shows the group characteristics (A–C) and
Table S1 individual characteristics. Details of the selection
process are depicted in the Fig. S1.
Medical records, lung function data, and paraffin-
embedded endobronchial biopsies (EBB) were available from
all selected patients.
EBB staining, virtual microscopy, and interactive website
EBB slides were stained with hematoxylin and eosin (H&E).
An experienced pulmonary pathologist (WT) checked the
quality of the slides for each patient and selected the best
specimen based on size, intactness, and presence of mucosal







Characteristics Asthma COPD Asthma COPD Asthma COPD
Age, years 53 (50–64) 56 (47–63) 61 (54–68) 61.5 (56–72) 29.5 (25–44) 63 (53–64)
Sex, M/F 6M, 2F 5M, 3F 5M, 3F 8M, 0F 4M, 4F 6M, 2F
FEV1/FVC,% 64 (48–69) 62 (48–70) 53 (40–66) 53 (36–69) 81 (75–98) 41 (30–47)
FEV1, %pred 83 (60–108) 82 (70–106) 83 (43–99) 71 (46–90) 105 (95–122) 45 (41–50)
Pack-years 31 (10–44) 29 (15–43) 20 (12–64) 38 (19–51) 0.0 (0.0–0.0) 32 (21–56)
Current smoking, n ex smoking, n 8 current, 0 ex 8 current, 0 ex 6 current, 2 ex 6 current, 2 ex 0 current, 0 ex 8 current, 0 ex
Data presented as median (minimum-maximum) except for sex (M male, F female) and smoking (current, ex smoking). Group A: asthma and COPD
patients without ICS use, age > 45 years, post bronchodilator (BD) FEV1/FVC <70 %, and >10 pack-years smoking. Group B: asthma and COPD
patients with the same criteria, but subjects had to use ICS during last 30months. Group C: “classical” asthma patients without ICS use, and with post BD
FEV1 > 90 % predicted, age < 45 years, 0 pack-years smoking, and atopy. Classical asthma was contrasted with classical COPD: no ICS use, post BD
FEV1 < 50 % predicted, age > 45 years, current smoking with >10 pack-years, and no atopy
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and submucosal layers. This quality check was performed
without knowing the diagnosis or paying attention to the pos-
sible diagnosis. Entire biopsies were scanned using Aperio
ScanScope Digital Slide Scanner at ×40 magnification. After-
wards, the images were uploaded to a specially designed in-
teractive website, allowing to view the slides at different
magnifications and to navigate into different areas of the bron-
chial biopsy like with a normal microscope (Fig. 1). Quality of
our web-based virtual microscopy was checked by an experi-
enced independent pulmonary pathologist who compared all
48 slide images with series of biopsies from the original glass
slides by microscope.
Table 2 Design of the study
Time (weeks) Examination of slides Description
Phase 1 2 Pairwise (2 × 24 slides) Matched asthma and COPD slides were offered pairwise. The pathologists were informed
about this and could only opt for asthma or COPD, thus chose for two options per pair.
Once chosen, the pathologists were not able to change their choice or go back to slides
shown earlier.
Interval 4–6
Phase 2 4 Randomlymixed (48 slides) The 48 slides were randomly mixed. The pathologists were informed about this and had to
opt for asthma or COPD per slide. Once chosen, the pathologists were not able to change
their choice or go back to slides shown earlier.
Interval 4–6
Phase 3a 2 Randomlymixed + criterion
list (48 slides)
Conform phase 2. Additionally, the pathologists were asked per slide to score for the
presence or absence of a criterion that drove their diagnosis (Box 1). After scoring the
criterion list they had to choose for asthma or COPD and to give their level of certainty
(VAS 0–10).
Interval 4–6
Phase 3b 2 Randomlymixed + criterion
list (24 slides)
Conform phase 3a. This phase aimed to test repeatability.
Interval 4–6
Phase 4 2 Pairwise (2 × 24 slides) Conform phase 1. This phase aimed to test repeatability (and/or potential learning effects).
Totally 28–
36 weeks
Fig. 1 Example slide on
interactive website. Screenshot of
the interactive website, showing a
slide with a representative
bronchial biopsy at ×20
magnification. The small image in
the lower part of the picture is the
overview window, showing the
current position and size of the
large window. The website
allowed to view the slides at
different magnifications and to
navigate into different areas of the
bronchial biopsy like a normal
microscope
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Study protocol
Ten pathologists from different countries (Netherlands,
Brazil, Canada, Austria, Switzerland), five of them special-
ized in pulmonary pathology, participated in the study and
used our interactive website following a strict protocol
(Table 2). The pathologists were informed about the de-
sign of the study but had no clinical information (age, sex,
ICS use, smoking, lung function). In phases 1 and 4, the
pathologists were offered 48 slides, i.e., 24 pairs of
matched asthma and COPD patients, and were asked to
indicate per pair which one was asthma and which one
COPD. In phases 2 and 3, all 48 slides were offered in a
randomly mixed order and the pathologists were asked to
choose for either asthma or COPD. In phase 3, the pa-
thologists were additionally asked to indicate the presence
or absence of a pathological criterion using the criteria list
of Bourdin’s study [13], with small modifications (Box 1).
In addition, they were asked how sure they felt about their
diagnosis using a 0–10 visual analog scale (VAS) score (0
not sure, 10 very sure) and to rank what they considered
the three most relevant features (Fig. 2).
Box 1
Questionnaire for pathologists
Indicate per criterion if it is abnormally (disease-related) present (yes/no)
Epithelium
• Denudation (loss of epithelium, including loss of super-basal epithelium) 
• Squamous metaplasia
• Hyperplasia (=thickened epithelium)











How sure are you about the diagnosis (score 1-10): ................................





Data from the interactive website were automatically and anony-
mously saved to an Excel file (MS Excel 2010) and transferred to
SPSS software (version 19.0; SPSS Inc., Chicago, IL). The
individual data was computed to a concordant or discordant diag-
nosis of asthma or COPD (i.e., concordant between pathological
and clinical diagnosis), and results were expressed as the mean
percentage of the concordant diagnosis. In phase 3, the reported
presence of each pathological criterion was compared between
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slides of asthma and COPD using the Mann-Whitney test. Sensi-
tivity, specificity, and accuracy of each pathological criterion for
pathologists making a concordant diagnosis of asthma were cal-
culated. A high sensitivity for asthma indicated automatically a
high specificity for COPD and vice versa. Pathological criteria
with a p value <0.2 in the univariate analysis were entered in a
logistic regression analysis on the presence of asthma. Pathologi-
cal criteria which contributed independently to a concordant diag-
nosis of asthma or COPDwere combined to find higher accuracy
rates for the concordant diagnosis. Selection of combined criteria
was based on the highest Wald value in the regression analyses.
Analyses were performed in the total group of patients,
within patient groups (A–C), and between pathologists (gen-
eral, specialized). Intra- (between phases 3a and 3b, see Box
1) and inter-observer (within phase 3a) agreements were
assessed with Cohen’s kappa test and Fleiss’ kappa, respec-
tively. The significance level was set at 0.05.
Results
Concordant diagnoses (pathology concordant with clinical
diagnosis)
Table 3 shows the percentage of concordant diagnoses per phase,
for each disease group (A–C) per pathologist group. The percent-
ages of concordant diagnoses, per pathologist, per phase, are
shown in Fig. S2. The percentage of concordant diagnoses of
asthma or COPD, per pathologist group, in phase 3a is shown in
Table S2. Overall, the highest number of concordant diagnoses
was observed in phase 4, particularly by pulmonary pathologists.
The highest score for asthma was observed in phase 3a, in the
classical asthma/COPD group (C), by pulmonary pathologists,
91.4 %. The highest score for COPDwas also observed in phase
3a, in the non-classical asthma/COPD group of ICS users (B),
with no difference between pulmonary and general pathologists.
Feeling sure about the diagnosis of asthma (in asthma andCOPD
cases together) was rated on a VAS scale from 1 to 10. In groups
A–C, the mean (SD) VAS score for asthma was 5.6 (2.5), 5.2
(2.0), and 6.1 (2.4), respectively. For COPD, this was 5.9 (2.4),
5.8 (2.1), and 5.0 (2.6).
Pathological criteria in phase 3
Table 4 shows the reported presence of pathological criteria in
the airway wall biopsies in asthma or COPD per disease group
(4A–C). Criteria that differed significantly between asthma
and COPD were not comparable between the three groups.
Eosinophilia was significantly more frequently reported in
asthma in groups B + C but not in A (subjects with asthma
and COPD in B used ICS, in contrast to subjects in A + C).
Submucosal inflammation was significantly more frequently
reported in asthma in groups B + C than in group A, yet more
frequently in COPD in group A. Table S3 and Box 2 show
which pathological criteria significantly contribute to a con-
cordant diagnosis of asthma or COPD in a multiple regression
Fig. 2 Example slide on
interactive website including the
list with pathological criteria.
Screenshot of the interactive
website, showing a slide (phase
3a) with a representative
bronchial biopsy at ×10
magnification. The small image in
the lower part of the picture is the
overview window, showing the
current position and size of the
large window. At the right side of
the slide the pathologists may
record the observed abnormal
presence of 12 pathological
criteria (yes/no), the diagnosis of
asthma or COPD, how sure they
feel about the diagnosis, and rank
the 3 most relevant features
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model. Significant criteria present in all groups were goblet
cells, inflammatory infiltrate, and glands. Significant criteria
present in two groups were eosinophils (group B + C), and in
one group squamous metaplasia (group A), BM thickening
(group B), hyperplasia (group C), smooth muscle (group C),
and submucosal fibrosis (group C). Significant (p < 0.05)
Wald values of these models are also shown in Table 4.
Sensitivity, specificity, and accuracy of criteria
for a concordant diagnosis
Table 4 shows the sensitivity, specificity, and accuracy for
asthma/COPD diagnosis for groups A–C. Pathological criteria
with high accuracy differed importantly between groups A–C.
In group A (no ICS use), glands, goblet cells, squamous meta-
plasia, and submucosal infiltrate showed the highest accuracy.
In group B (with ICS use), the highest accuracy was provided
by submucosal inflammation, basement membrane thicken-
ing, eosinophilia, and glands. In group C (classical asthma
and COPD), the highest accuracy was shown by submucosal
fibrosis, epithelial hyperplasia, eosinophilia, and glands.
Combinations of relevant pathological criteria did improve
sensitivity or specificity, but in general not accuracy
(Table S4).
Agreement between and repeatability within pathologists
Agreement between pathologists for a concordant diagnosis
of asthma or COPD in groups A–C was 0.40, 0.45, and 0.48,
respectively. This was 0.33, 0.45, and 0.72 for asthma and
0.60, 0.57, and 0.27 for COPD, respectively. Repeatability
within pathologists for a concordant diagnosis in groups A–
C was 0.75, 0.78, and 0.80 respectively. This was 0.75, 0.70,
and 0.80 for asthma and 0.70, 0.85, and 0.80 for COPD, re-
spectively. Agreement between and repeatability within pa-
thologists for the reported presence of pathological criteria in
groups A–C is presented in Table 4. Overall agreement in
groups A–C varied between 0.61 and 0.92. Overall repeatabil-
ity in groups A–C varied between 0.68 and 0.95.
Discussion
Asthma and COPD are obstructive airway diseases with clear
differences in etiology and pathophysiology, yet at older age,
they frequently are difficult to discriminate, the currently so-
called asthma-COPD overlap syndrome (ACOS) [3]. In the
current study, there was no discussion about the original un-
derlying disease, as we had historical data from well-
characterized cohort studies. Therefore, we had the opportu-
nity to carefully match bronchial biopsies from 24 asthma and
24 COPD patients taking age, FEV1, ICS use, and smoking
habits into account. Ten pathologists, not informed about the
individual clinical background of the patients, but knowing
the study design, were asked to diagnose asthma or COPD.
The important outcome of this study is that histological exam-
ination of bronchial biopsies alone does not allow differenti-
ating between asthma and COPD. However, as recognition of
the specific histological criteria was good, diagnostic value
can be expected to improve when selected pathological
criteria are applied and adequate clinical information is pro-
vided, in which in particular, knowledge about the use of ICS
is essential.
In this study, we aimed for high-quality matching of
asthma and COPD patients, considering age, smoking,
ICS use, and airway obstruction as important modula-
tors of airway inflammation and remodeling. This
matching is important because it fits with the original
question of the study: whether it is possible for pathol-
ogists to discriminate between older asthma patients
with fixed airway obstruction and COPD patients, using
bronchial biopsies. We designed our study into four
phases, gradually increasing the level of difficulty and
anticipated that a head-to-head comparison of two
paired slides, one from an asthma patient and one from
a COPD patient, would help to discriminate between the
two diseases. Interestingly, this was not the case. Suc-
cess rates of scoring of the paired slides were not
higher than those of randomly mixed slides. Further-
more, we anticipated that systematic scoring of textbook
pathological criteria for asthma or COPD would help to
set the correct (=concordant) diagnosis; however, this
was not the case.
The overall percentages of a diagnosis of asthma or COPD
concordant with the clinical diagnosis were low, taking into
account a 50 % concordance by chance. We expected the
highest percentage of concordant diagnoses in young asthmat-
ic patients without ICS use and with a normal lung function,
assuming that the recognition of the underlying disease is
easier when inflammation is not treated with ICS or changed
by age- and smoking-related remodeling processes. Indeed,
the highest percentage of a concordant diagnosis for asthma
in the randomly mixed slides was observed in the group of
classical cases (group C, without ICS) and the lowest in the
group of asthma subjects who used ICS clinically which are
difficult to diagnose (group B). Interestingly, this contrasted
with the findings for COPD, where the highest percentage of
concordant diagnoses occurred in the group of ICS users. It is
not clear at first sight why ICS use reduced the percentage of
concordant diagnosis for asthma, yet improved this for COPD.
This may well be because corticosteroids reduce eosinophil
survival but prolong neutrophil survival; hence, ICS use may
have reduced eosinophilia in asthma and increased
neutrophilia in COPD [18], eosinophilia being considered a
hallmark for asthma and neutrophilia for COPD. This con-
trasting effect of ICS use on giving a concordant diagnosis
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of asthma or COPD is an important finding of our study,
which—it goes without saying—emphasizes the need for ef-
fective transfer of adequate clinical data from clinicians to
pathologists.
The reported presence of pathological criteria was signifi-
cantly different between slides from asthma and COPD pa-
tients, in striking contrast with the low percentage of concor-
dant diagnoses of asthma and COPD based on biopsies alone.
Additionally, the agreement between the 10 pathologists (inter-
observer variability) and repeatability within pathologists
(intra-observer variability) was good to excellent for many
pathological criteria, independent of a concordant diagnosis.
Thus, all expertise to allow a concordant diagnosis of asthma
or COPD was present, yet the pathologists appeared to need
additional information to be able to apply this expertise suc-
cessfully, considering the relatively low percentage of concor-
dant diagnoses. A priory, one might expect that the diagnosis
of pathologists based upon histology only might be more ac-
curate because it allows integration of all relevant information
from all parts of a biopsy. Apparently, this is a difficult task,
which is in particular complicated when clinical characteristics
like age, smoking, ICS use, and airway obstruction, that affect
accuracy and significance of potentially useful pathological
criteria, are not known, as shown in the present study.
Next, we tried to identify pathologists with a higher per-
centage of concordant diagnoses in order to learn and copy
their strategy. Beforehand, we expected that pulmonary pa-
thologists would do better than general pathologists. Indeed,
at a group level, the mean scores of the pulmonary pathologist
group tended to be higher in every phase of the study, and the
pathologists with the highest percentages of concordant diag-
noses were almost always the pulmonary pathologists. For
example, one of the pulmonary pathologists (pathologist B
in Table S2) had high accuracy rates, but importantly, in the
subgroup of patients who did use ICS (group B), this pathol-
ogist had poor results, again demonstrating the importance of
knowledge of the clinical background of patients. The patho-
logical criteria that were most frequently ranked as important
for the diagnosis by the best scoring pathologists were squa-
mous metaplasia in group A (without ICS use), basement
membrane thickening in group B (with ICS use), and submu-
cosal fibrosis in group C (with “classical” asthma and COPD).
This is not unexpected as these pathological criteria demon-
strated also high accuracy rates at a group level. Finally, we
tried to improve accuracy rates by combining pathological
criteria that independently associated with the clinical diagno-
sis of asthma or COPD. Whereas it was not difficult to find
combinations with a very high sensitivity or specificity rates,
the accuracy rates of these combinations were generally not
better than the individual pathological criteria.
We hypothesize that pathologists may improve their ability
to differentiate asthma from COPD if they use selected path-
ological criteria, i.e., those with a high accuracy rate for con-
cordance, provided that the relevant clinical information is
known. In non ICS users with fixed airway obstruction the
abnormal presence of goblet cells directs towards an asthma
diagnosis, whereas glands, squamous metaplasia, and submu-
cosal infiltrate direct towards COPD (Box 2). In ICS users
Table 3 Percentage of
concordant diagnoses in different
phases of the study
Phase 1 Phase 2 Phase 3a Phase 4
Pairwise Asthma COPD Asthma COPD Pairwise
All pathologists All 68.7 65.6 62.5 63.5 62.5 72.6
A (ICS−) 65.0 67.5 62.5 56.3 65.0 63.8
B (ICS+) 73.8 52.5 66.2 52.5 72.5 76.3
C (classical) 67.1 78.6 58.7 84.3 50.0 78.6
Lung pathologists All 71.3 66.1 60.0 70.4 61.7 76.5
A (ICS−) 62.5 67.5 57.5 67.5 57.5 62.5
B (ICS+) 80.0 52.5 65.0 55.0 72.5 85.0
C (classical) 71.4 80.0 57.5 91.4 55.0 82.9
General pathologists All 66.1 65.2 65.0 56.5 63.3 68.7
A (ICS−) 67.5 67.5 67.5 45.0 72.5 65.0
B (ICS+) 67.5 52.5 67.5 50.0 72.5 67.5
C (classical) 62.9 77.1 60.0 77.1 45.0 74.3
Values are percentage of concordant diagnoses. Italic values: p < 0.05 between A, B, and C within 3a phase.
Group A: asthma and COPD patients without ICS use, age > 45 years, post bronchodilator (BD) FEV1/FVC
<70 %, and >10 pack-years smoking. Group B: asthma and COPD patients with the same criteria, but subjects
had to use ICS during last 30 months. Group C: “classical” asthma patients without ICS use, and with post BD
FEV1 > 90 % predicted, age < 45 years, 0 pack-years smoking, and atopy. Classical asthma was contrasted with
classical COPD: no ICS use, post BD FEV1 < 50 % predicted, age > 45 years, current smoking with >10 pack-
years, and no atopy
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with fixed airway obstruction, the abnormal presence of sub-
mucosal infiltrate, basement membrane thickening, eosino-
phils, and glands direct towards asthma diagnosis. In classical
cases, the diagnosis is already known on the basis of clinical
characteristics. Nevertheless, the clinical diagnosis can be
confirmed by the observation of submucosal infiltrate and
eosinophils indicating asthma, whereas submucosal fibrosis,
hyperplasia, and glands indicate COPD.




















Group A (non-ICS users)
Denudation 85.0 83.8 1.1 (0.47–2.58) 85.0 16.3 50.6 0.76 (0.77; 0.76) 0.90 (0.95; 0.85)
Squamous Metaplasia 22.5 53.8 0.25 (0.13–0.49) 7.74 77.5 53.8 65.6 0.72 (0.77; 0.68) 0.80 (0.90; 0.70)
Hyperplasia 52.5 55.0 0.90 (0.49–1.69) 47.5 55.0 51.2 0.63 (0.73; 0.54) 0.73 (0.75; 0.70)
Goblet cells 60.0 32.5 3.11 (1.63–5.95) 5.54 60.0 67.5 63.7 0.85 (0.87; 0.84) 0.85 (0.90; 0.80)
BM thickening 73.8 67.5 1.35 (0.68–2.68) 73.8 32.5 53.1 0.67 (0.69; 0.64) 0.85 (0.85; 0.85)
Inflammatory infiltrate 53.8 72.5 0.44 (0.23–0.85) 11.84 46.3 72.5 59.4 0.61 (0.53; 0.69) 0.78 (0.60; 0.95)
Eosinophils 22.5 12.5 2.03 (0.87–4.73) 22.5 87.5 55.0 0.72 (0.64; 0.79) 0.85 (0.75; 0.95)
Smooth muscle 60.0 81.3 0.35 (0.17–0.71) 40.0 81.3 60.6 0.76 (0.78; 0.74) 0.85 (0.80; 0.90)
Glands 23.8 72.5 0.12 (0.06–0.24) 21.62 76.3 72.5 74.4 0.85 (0.93; 0.76) 0.90 (1:00; 0.80)
Sub mucosal fibrosis 67.5 58.8 1.46 (0.76–2.78) 32.5 58.8 45.6 0.63 (0.66; 0.60) 0.75 (0.85; 0.65)
Group B (ICS users)
Denudation 71.3 58.8 1.74 (0.90–3.36) 71.3 41.3 56.2 0.62 (0.61; 0.63) 0.73 (0.65; 0.80)
Squamous metaplasia 33.8 35.0 0.95 (0.49–1.82) 66.3 35.0 50.6 0.80 (0.80; 0.81) 0.85 (0.70; 1.00)
Hyperplasia 51.3 53.8 0.90 (0.49–1.68) 48.8 53.8 51.2 0.67 (0.71; 0.63) 0.90 (0.85; 0.95)
Goblet cells 72.5 60.0 1.76 (0.90–3.41) 72.5 40.0 56.2 0.72 (0.68; 0.76) 0.60 (0.60; 0.60)
BM thickening 57.5 25.0 4.06 (2.07–7.95) 18.24 57.5 75.0 66.2 0.71 (0.78; 0.64) 0.75 (0.80; 0.70)
Inflammatory infiltrate 63.8 23.8 5.65 (2.84–11.23) 19.86 63.8 76.3 70.0 0.71 (0.73; 0.70) 0.83 (0.80; 0.85)
Eosinophils 30.0 3.8 11.0 (3.16–38.34) 4.27 30.0 96.3 63.1 0.85 (0.76; 0.93) 0.83 (0.70; 0.95)
Smooth muscle 66.3 61.3 1.24 (0.65–2.37) 66.3 38.8 52.5 0.77 (0.86; 0.68) 0.80 (0.80; 0.80)
Glands 48.8 33.8 1.87 (0.99–3.53) 8.88 48.8 66.3 57.5 0.81 (0.79; 0.83) 0.90 (0.90; 0.90)
Sub mucosal fibrosis 66.3 67.5 0.94 (0.49–1.83) 33.8 67.5 50.6 0.65 (0.64; 0.66) 0.78 (0.85; 0.70)
Group C (classical group)
Denudation 91.4 80.0 2.67 (0.98–7.25) 91.4 20.0 53.3 0.76 (0.86; 0.68) 0.75 (0.80; 0.70)
Squamous metaplasia 0.0 17.5 0.000 (0.000- -) 100.0 17.5 56.0 0.92 (1.00; 0.86) 0.95 (1.00; 0.90)
Hyperplasia 10.0 61.3 0.07 (0.03–0.17) 16.95 90.0 61.3 74.7 0.80 (0.84; 0.77) 0.88 (0.95; 0.80)
Goblet cells 54.3 43.8 1.53 (0.80–2.91) 54.3 56.3 55.3 0.74 (0.73; 0.75) 0.68 (0.70; 0.65)
BM thickening 74.3 71.3 1.17 (0.57–2.40) 74.3 28.8 50.0 0.71 (0.78; 0.66) 0.78 (0.80; 0.75)
Inflammatory infiltrate 91.4 65.0 5.74 (2.21–14.92) 8.88 91.4 35.0 61.3 0.72 (0.84; 0.62) 0.73 (0.80; 0.65)
Eosinophils 47.1 20.0 3.57 (1.73–7.34) 3.97 47.1 80.0 64.7 0.71 (0.58; 0.83) 0.80 (0.60; 1.00)
Smooth muscle 87.1 77.5 1.97 (0.82–4.72) 6.34 87.1 22.5 52.7 0.77 (0.83; 0.71) 0.93 (0.85; 1.00)
Glands 10.0 43.8 0.14 (0.06–0.35) 8.66 90.0 43.8 65.3 0.89 (0.89; 0.89) 0.93 (1.00; 0.85)
Sub mucosal fibrosis 14.3 78.8 0.04 (0.02–0.11) 19.98 85.7 78.8 82.0 0.72 (0.77; 0.68) 0.78 (0.65; 0.90)
*Repeatability and agreement data presented for asthma and COPD together and separately (asthma; COPD). ORs > 1 indicate a positive association
with the presence of asthma; OR < 1 indicate a positive association with the presence of COPD. Sensitivity and specificity for asthma are calculated for
the reported presence of variables with OR > 1. Sensitivity and specificity for COPD are calculated for the reported presence of variables with OR < 1.
Significant (p < 0.05)
Wald values were derived from logistic regression analyses on the concordant diagnosis of asthma and COPD (Table S4)
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Box 2
Abnormal presence
of pathological criteria 
in subjects aged >45 years 
with >10 pack-years smoking 
and post-bronchodilator FEV1/FVC <0.7
Non ICS-users 
- goblet cells asthma
- glands
- squamous metaplasia COPD
- submucosal infiltrate 
ICS-users 
- basement membrane thickening 
- submucosal infiltrate asthma
- eosinophils 
- glands
This study has a few limitations. First, one can argue
whether or not a physician’s diagnosis of asthma or COPD
is an adequate gold standard. Importantly, patient charts of
many years back showed that even patients with asthma and
fixed airway obstruction at current investigation had revers-
ible airway obstruction at a younger age. After accepting
that our physician’s diagnosis is reliable, one might still
argue that the selected cases are not the ones that normally
would need a pathological examination, because the clini-
cal diagnosis was already established with certainty. Unfor-
tunately, we have no biopsies available to compare cases
with certain versus uncertain clinical diagnosis. Our aim
however was to establish clues at the microscopical level
with strong relation with either asthma or COPD, to be used
as clues in difficult biopsies to direct towards a likely diag-
nosis. Secondly, one could argue that biopsies were not
examined by microscope but on screen, which reflects but
is not identical to the real-life situation in daily diagnostic
practice. This indeed should be validated as is indicated by
a recent guideline [19]. Nevertheless, in our approach, all
pathologists were exposed to identical images, which im-
proved standardization and allowed pathologists to scroll
easily through complete high-resolution slides and varying
magnification as in classical microscopy. Third, we did not
include slides from healthy controls or from subjects with
another lung disease. Consequently, the terms sensitivity
and specificity only refer to asthma and COPD, compatible
with our study question whether a pathologist is able to give
a concordant diagnosis of asthma or COPD. We therefore
consider our study design appropriate.
In conclusion, we show that the differentiation between
asthma and COPD, based on histopathological examination
only of a bronchial biopsy, without adequate clinical informa-
tion, is difficult. This contrasts with the high percentage of
concordant diagnosis observed for a number of reported path-
ological criteria. We postulate that the diagnostic value is like-
ly to improve when selected pathological criteria (Box 2) are
applied and adequate information is provided with respect to
the use of ICS. Prospective studies incorporating medical de-
cision techniques may validate algorithms that take these is-
sues into account.
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